HER-3 expression in HER-2-amplified breast carcinoma

HER-3 expression in HER-2-amplified breast carcinoma

Bibliographic Details
Main Authors:	Czopek, Jacek, Pawlęga, Janusz, Fijorek, Kamil, Püsküllüoğlu, Mirosława, Różanowski, Paweł, Okoń, Krzysztof
Format:	Online
Language:	English
Published:	Termedia Publishing House 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3934027/

Similar Items

Circadian Models of Serum Potassium, Sodium, and Calcium Concentrations in Healthy Individuals and Their Application to Cardiac Electrophysiology Simulations at Individual Level
by: Fijorek, Kamil, et al.
Published: (2013)

Biological characterisation of HER2 amplified breast cancer
by: Barros, Fabrício Félix Tabuada
Published: (2013)

Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial
by: Ochenduszko, Sebastian, et al.
Published: (2015)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
by: Lipton, Allan, et al.
Published: (2013)

Metastatic, Her-2 Amplified Lacrimal Gland Carcinoma with Response to Lapatinib Treatment
by: Dennie, Trevor
Published: (2015)

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
by: Canonici, Alexandra, et al.
Published: (2013)

Expression of HER2 in Colorectal Cancer Does Not Correlate with Prognosis
by: Kruszewski, Wiesław Janusz, et al.
Published: (2010)

HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer
by: Styczen, Hanna, et al.
Published: (2015)

AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models
by: Mu, Zhaomei, et al.
Published: (2014)

Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models
by: CRAFTER, CLAIRE, et al.
Published: (2015)

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
by: Green, Andrew R., et al.
Published: (2014)

A functional comparison between the HER2high/HER3 and the HER2low/HER3 dimers on heregulin-β1-induced MMP-1 and MMP-9 expression in breast cancer cells
by: Kim, Sangmin, et al.
Published: (2012)

Model-Based Analysis of HER Activation in Cells Co-Expressing EGFR, HER2 and HER3
by: Shankaran, Harish, et al.
Published: (2013)

Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells
by: Hosonaga, Mari, et al.
Published: (2014)

Effectiveness of EGFR/HER2-targeted drugs is influenced by the downstream interaction shifts of PTPIP51 in HER2-amplified breast cancer cells
by: Eric Dietel, et al.
Published: (2018-08-01)

Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas
by: Kountourakis, Panteleimon, et al.
Published: (2006)

HER2/neu expression correlates with vasculogenic mimicry in invasive breast carcinoma
by: Liu, Tieju, et al.
Published: (2013)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
by: Han, Sae-Won, et al.
Published: (2012)

Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer
by: Stenehjem, David D, et al.
Published: (2014)

Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer
by: Moi, Line L Haugan, et al.
Published: (2012)

Preclinical Therapy of Disseminated HER-2+ Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus
by: Nanni, Patrizia, et al.
Published: (2013)

Clinical and molecular characterization of HER2 amplified-pancreatic cancer
by: Chou, Angela, et al.
Published: (2013)

Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer
by: Tschui, J., et al.
Published: (2015)

WASF3 provides the conduit to facilitate invasion and metastasis in breast cancer cells through HER2/HER3 signaling
by: Teng, Yong, et al.
Published: (2016)

Novel agents that downregulate EGFR, HER2, and HER3 in parallel
by: Ferreira, Renan Barroso, et al.
Published: (2015)

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
by: Pinhel, Isabel, et al.
Published: (2012)

HER-2 gene amplification in human breast cancer without concurrent HER-2 over-expression
by: Luoh, Shiuh-Wen, et al.
Published: (2013)

Continuous quantification of HER2 expression by microfluidic precision immunofluorescence estimates HER2 gene amplification in breast cancer
by: Dupouy, Diego G., et al.
Published: (2016)

Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status
by: Laidi, Fatna, et al.
Published: (2014)

The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients
by: Machleidt, Anna, et al.
Published: (2013)

Protein secretion in human mammary epithelial cells following HER1 receptor activation: influence of HER2 and HER3 expression
by: Zhang, Yi, et al.
Published: (2011)

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
by: Serra, V, et al.
Published: (2011)

Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer
by: Xin Li, et al.
Published: (2018-08-01)

HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
by: Kurozumi, Sasagu, et al.
Published: (2016)

Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer
by: Nafi, Siti Norasikin Mohd, et al.
Published: (2014)

Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
by: Fehm, Tanja, et al.
Published: (2007)

Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer
by: Staaf, Johan, et al.
Published: (2011)

Genomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: field cancerization or contaminating tumor cells?
by: Sadanandam, Anguraj, et al.
Published: (2012)

Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer
by: Leung, Wing-yin, et al.
Published: (2015)

Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It
by: Luque-Cabal, María, et al.
Published: (2016)